Eosinophilic esophagitis

Česká verzia

Authors: A. Štrosová ¹; J. Martínek ¹; Š. Suchánek ¹; F. Závada ¹; M. Stefanová ¹; B. Bunganič ¹; I. Tučková ²; P. Hrabal ²; M. Zavoral ¹
Authors place of work: Interní klinika 1. LF UK a ÚVN Praha ¹; Oddělení patologie, ÚVN Praha ²
Published in the journal: Gastroent Hepatol 2011; 65(5): 272-278
Category: Clinical and Experimental Gastroenterology: Review Article

Summary

The article summarizes the “state of the art” concerning eosinophilic esophagitis and describes the results of our own prospective study. Eosinophilic esophagitis (EoE) is a rare and not very often diagnosed esophageal disorder. It is caused by chronic infiltration of the esophageal mucosa by eosinophils and it has typical clinical, endoscopic and histopathologic manifestations. EoE was firstly described in 1978. Traditionally, the definition of EoE has been set on the basis of an arbitrary limit of eosinophils (usually ≥ 15 eosinophils / high power field) in patients with typical symptomatology and without pathological gastroesophageal reflux (defined as negative pH-metry or by the absence of a clinical improvement during treatment with a proton pump inhibitor). Now, a new definition of EoE is being proposed where patients with gastroesophageal reflux and eosinophilic infiltration of the esophagus should also get a diagnosis of EoE. Furthermore, patients with EoE must not have eosinophilic infiltration in any of the remaining parts of the GIT. Patients with EoE usually complain about dysphagia and food impaction. The etiology and the prognosis are not clearly established. EoE’s course is usually chronic. Long lasting inflammation in the esophagus leads to changes of the esophageal wall and mucosa which become rigid as well as fragile. Therefore, mucosal lacerations or even perforations can easily occur. A risk of malignancy in patients with EoE has not yet been described and seems unlikely. EoE is detected in patients of all ages, including children with males predominating. An association with different kinds of allergies is typical. As an initial treatment option, a proton pump inhibitor is administered, and if necessary, corticosteroids (locally or systemic administration) are given. Other treatment modalities are rather experimental and are being tested in clinical trials (e.g. biologic therapy). Endoscopic dilatation is a treatment option for symptomatic patients with narrow or stenotic esophageal lumen. The prevalence of esophageal eosinophilia was 5.6% among patients referred for upper GI endoscopy. A majority of patients with eosinophils (> 15/HPF) were diagnosed with EoE. However, a high number of eosinophils was also observed in two patients with achalasia and in one patient with Barrett’s esophagus. In accordance with other authors, we confirmed the majority of patients with EoE presents with dysphagia/food impaction (90%), while an allergy was present in 50% of our patients. Almost all patients responded favourably to treatment with a proton pump inhibitor.

Key words:
eosinophilic esophagitis – dysphagia – reflux esophagitis – esophageal perforation

Zdroje

1. Remedios M, Campbell C, Jones DM et al. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionáte. Gastrointestinal Endoscopy 2006; 63(1): 3–12.

2. Liacouras CA, Furuta GT, Hirano I et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128(1): 3–20.

3. Dranove JE, Horn DS, Davis MA et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 2009; 154(1): 96–100.

4. Hirano I. Eosinophilic esophagitis and gastroesophageal reflux disease: there and back again. Clin Gastroenterol Hepatol 2011; 9(2): 99–101.

5. Remedios M, Jones D, Kerlin P. Eosinophilic oesophagitis: epidemiology, pathogenesis and management. Drugs 2011; 71(5): 527–540.

6. Chehade M. Epidemiology and etiology of eosinophilic esophagitis. Gastrointest Endosc Clin N Am 2008; 18(1): 33–44.

7. Straumann A, Spichtin HP, Grize L et al. Natural history of primary eosinophilic esophagitis: A follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125(6): 1660–1669.

8. Veerappan GR, Perry JL, Baker TP et al. Prevalence of Eosinophilic Esophagitis in an Adult Population Undergoing Upper Endoscopy: A Prospective Study. Clin Gastroenterol Hepatol 2010; 7(4): 420–426.

9. Gutierrez-Ramos JC, Lloyd C, Gonzalo JA et al. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunology Today 1999: 20(11): 500–504.

10. Blanchard C, Wang N, Stringer KF et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006; 116: 536–547.

11. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392(6676): 565–568.

12. Mishra A. Mechanism of eosinophilic esophagitis. Immunol Allergy Clin North Am 2009; 29(1): 29–40.

13. Dellon ES, Chen X, Miller CR et al. Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. Am J Gastroenterol 2011; 106(2): 264–271.

14. Martinek J, Strosova A, Kostalova K et al. Significant Esophageal Eosinophilia and Typical Endoscopic Features are Highly but Not Exclusively Specific for Eosinofilic Esophagitis. Gastroenterology 2010; 138(5); Suppl 1: S177–178.

15. Furuta GT, Liacouras CA, Collins MH et al. Eosinophilic esophagitis in children and adults : a systematic review and konsensus recommendatins for diagnosis and treatement. Gastroenterology 2007; 133(4): 1342–1363.

16. Straumann A. The natural history and complications of eosinophilic esophagitis. Gastrointest Endosc Clin N Am 2008; 18(1): 99–118.

17. Penfield JD, Lang DM, Goldblum JR et al. The role of allergy evaluation in adults with eosinophilic esophagitis. J Clin Gastroenterol 2010; 44(1): 22–27.

18. Molina-Infante J, Ferrando-Lamana L, Ripoll C et al. Esophageal Eosinofilic Infiltration Respons to Proton Pump Inhibition in Most Adults. Clin Gastroenterol Hepatol 2011; 9(2): 110–117.

19. Zhang X, Cheng E, Huo X et al. In esophageal squamous epithelial cell lines from patients with eosinophilic esophagitis (EoE), omeprazole blocks the stimulated secretion of eotaxin-3: a potential anti-inflammatory effect of omeprazole in EoE that is independent of acid inhibition. Gastroenterology 2010; 138 (Suppl 1): S122.

20. Straumann A, Degen L, Felder S et al. Budesonide as induction treatment for active eosinophilic esophagitis in adolescents and adults: a randomized, doubleblind, placebo-controlled study (Bee-I trial). Gastroenterology 2008; 134: A104.

21. Straumann A, Conus S, Degen L et al. Budesonide Is Effective in Adolescent and Adult Patients With Active Eosinophilic Esophagitis. Gastroenterology 2010; 139(5): 1526–1537.

22. Remedios M, Jones D, Kerlin P. Eosinophilic oesophagitis: epidemiology, pathogenesis and management. Drugs 2011; 71(5): 527–540.

23. Straumann A, Conus S, Grzonka P et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010; 59(1): 21–30.

24. Lucendo AJ, De Rezende LC, Jiménez-Contreras S et al. Montelukast Was Inefficient in Maintaining Steroid-Induced Remission in Adult Eosinophilic Esophagitis. Dig Dis Sci 2011; [Epub ahead of print].

25. Assa'ad AH, Gupta SK, Collins MH et al. An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis. Gastroenterology 2011; [Epub ahead of print].

26. Hirano I. Dilation in eosinophilic esophagitis: to do or not to do? Gastrointest Endosc 2010; 71(4): 713–714.

27. Jacobs JW Jr., Spechler SJ. A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. Dig Dis Sci 2010; 55(6): 1512–1515.

28. Landres RT, Kuster GGR, Strum WB. Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology 1978; 74(6): 1298–1301.